Curis Q3 2024 Earnings Preview
| CRIS Stock | USD 3.43 0.16 4.89% |
Slightly above 55% of Curis' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Curis Inc suggests that some traders are interested. Curis' investing sentiment can be driven by a variety of factors including economic data, Curis' earnings reports, geopolitical events, and overall market trends.
Curis |
Curis is scheduled to announce Q3 earnings results on Thursday, November 14th, before market open.
Read at seekingalpha.com
 |
Curis Fundamental Analysis
We analyze Curis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Curis is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Curis Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Curis stock to make a market-neutral strategy. Peer analysis of Curis could also be used in its relative valuation, which is a method of valuing Curis by comparing valuation metrics with similar companies.
Peers
Curis Related Equities
| MREO | Mereo BioPharma | 6.16 | ||||
| XFOR | X4 Pharmaceuticals | 6.12 | ||||
| ADAP | Adaptimmune Therapeutics | 1.75 | ||||
| ARTL | Artelo Biosciences | 1.69 | ||||
| INZY | Inozyme Pharma | 1.54 | ||||
| DAWN | Day One | 1.05 | ||||
| AFMD | Affimed NV | 0.91 | ||||
| TERN | Terns Pharmaceuticals | 0.64 | ||||
| CRVS | Corvus Pharmaceuticals | 2.57 | ||||
| LPTX | Leap Therapeutics | 4.35 | ||||
| APTO | Aptose Biosciences | 4.55 | ||||
| PDSB | PDS Biotechnology | 10.12 |
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.